Skip to content

The Clinical Significance of Portal Hypertension After Cardiac Surgery: a Multicenter Prospective Observational Study

The Clinical Significance of Portal Hypertension After Cardiac Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03656263
Acronym
TECHNO-MULTI
Enrollment
360
Registered
2018-09-04
Start date
2018-11-14
Completion date
2021-02-20
Last updated
2021-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Congestive Heart Failure, Right Heart Failure, Surgery--Complications, Venous Congestion

Keywords

echocardiography, Portal Doppler, Cardiac surgery

Brief summary

Portal flow pulsatility detected by Doppler ultrasound is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse outcomes based on previous studies performed at the Montreal Heart Institute. This multicenter prospective cohort study aims to determine if portal flow pulsatility after cardiopulmonary bypass separation is associated with a longer requirement of life support after cardiac surgery.

Detailed description

Hypothesis: Portal flow pulsatility detected by Doppler ultrasound during cardiac surgery is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse clinical outcomes. Background: Peri-operative right ventricular failure is associated with a high mortality rate. In this context, organ perfusion is hampered by both the reduction of cardiac output and venous congestion from the elevation of central venous pressure. The clinician's objective is to appreciate the hemodynamic impact on end-organs in an effort to adjust the therapy accordingly since the ultimate goal is to optimize their perfusion. Based on this rationale, organ specific blood flow assessment using Doppler ultrasound could be used to personalize management. In order to non-invasively assess the presence of cardiogenic portal hypertension, Doppler ultrasound can be used to detect portal flow pulsatility, an abnormal variation in the velocity of blood flow within the main portal vein. In two single-center cohort studies, the presence of portal flow pulsatility after cardiac surgery was independently associated with post-operative complications such as major bleeding, acute kidney injury (AKI) and delirium as well as increased length of intensive care unit (ICU) stay. Specific Objectives: This multi-center cohort study aim to determine whether the association between portal flow pulsatility and organ dysfunction seen in previous studies is present across multiple cardiac surgery centers.

Interventions

DIAGNOSTIC_TESTDoppler assessment of portal vein flow

Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.

Sponsors

Montreal Heart Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patients (≥18 years old) and able to give informed consent undergoing cardiac surgery with the use of CPB for whom peri-operative TEE is planned. * High surgical risk defined as at least one of the following: 1. Multiple surgical procedures planned 2. EuroSCORE II ≥ 5% 3. Known pulmonary hypertension (mPAP\>25mmHg or sPAP\>40mmHg).

Exclusion criteria

* Patient with a critical pre-operative state defined as vasopressor requirement, mechanical circulatory support, dialysis, mechanical ventilation or cardiac arrest necessitating resuscitation. * Patient with known condition that could interfere with portal flow assessment or interpretation (liver cirrhosis, portal vein thrombosis) * Planned cardiac transplantation * Planned ventricular assist device implantation

Design outcomes

Primary

MeasureTime frameDescription
Duration of invasive life support after cardiac surgery. (Tpod)Up to 28 daysDefined as the time of Persistent Organ Dysfunction (POD) or Death

Secondary

MeasureTime frameDescription
Acute kidney injury according to KDIGO serum creatinine criteriaUp to 28 daysStage 1: ≥50% or 27 umol/L increases in serum creatinine Stage 2: ≥100% increase in serum creatinine Stage 3 ≥200% increase in serum creatinine or an increase to a level of ≥254 umol/L or dialysis initiation.
Major bleeding defined by the Bleeding Academic Research Consortium (BARC)Up to 28 daysPerioperative intracranial bleeding within 48h Reoperation after closure of sternotomy for the purpose of controlling bleeding Transfusion of ≥5 units of whole blood of packed red blood cells within a 48 hours period Chest tube output ≥2L within a 24 hours period
Surgical reintervention for any reasonsUp to 28 daysRe-operation after the initial surgery for any cause
Deep sternal wound infection or mediastinitisUp to 28 daysDiagnosis of a deep incisional surgical site infection or mediastinitis by a surgeon or attending physician.
DeliriumUp to 28 daysDefined as a intensive care delirium screening checklist (ICDSC) score of ≥4 in the week following surgery or positive result for the Confusion Assessment Method for the ICU (CAM-ICU)
All cause deathUp to 28 daysDeath from any cause
Total duration of ICU stay in hoursUp to 28 daysNumber of hours passed in the ICU
Duration of hospital stay (in days)Up to 28 daysNumber of days hospitalized from the day of surgery to discharge
Duration of mechanical ventilation (in hours)Up to 28 daysNumber of hours of mechanical ventilation
A composite outcome of major morbidity or mortality (41): including death, prolonged ventilation, stroke, renal failure (Stage ≥2), deep sternal wound infection and reoperation for any reason.Up to 28 daysComposite endpoint after cardiac proposed by the Society of Thoracic Surgeons
StrokeUp to 28 daysA central neurologic deficit persisting longer than 72 hours

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026